Table A1.

Grade ≥ 2 Toxicities Attributed to MDX-1106

Disorder	Dose (mg/kg)								Total No. of Patients (N = 39)
	0.3 (n = 6)		1.0 (n = 6)		3 (n = 6)		10 (n = 21)
	No.	%	No.	%	No.	%	No.	%	No.	%
Blood
Anemia
Grade 2	0		1	16.7	0		1	4.8	2	5.1
Grade 3	1	16.7	0		0		0		1	2.6
CD4 decrease
Grade 2	0		2	33.3	1	16.7	4	19.0	7	17.9
Grade 3	1	16.7	0		0		6	28.6	7	17.9
Lymphopenia
Grade 2	2	33.3	0		2	33.3	5	23.8	9	23.1
Grade 3	0		0		0		1	4.8	1	2.6
Neutropenia
Grade 2	1	16.7	0		0		0		1	2.6
Cardiovascular
Hypertension
Grade 2	1	16.7	0		0		0		1	2.6
Endocrine and metabolic
Hypocalcemia
Grade 3	0		0		0		1	4.8	1	2.6
Hyperglycemia
Grade 2	0		0		0		1	4.8	1	2.6
Hypothyroidism
Grade 2	0		0		0		1	4.8	1	2.6
Gastrointestinal
Ascites
Grade 3	1	16.7	0		0		0		1	2.6
Colitis
Grade 3	0		1	16.7	0		0		1	2.6
Stomatitis
Grade 2	0		0		0		1	4.8	1	2.6
General
Fatigue
Grade 2	0		0		3	50.0	2	9.5	5	12.8
Grade 3	0		0		0		1	4.8	1	2.6
Infusion site reaction
Grade 2	0		0		0		2	9.5	2	5.1
Pyrexia
Grade 2	0		1	16.7	0		0		1	2.6
Hepatobiliary
Liver disorder
Grade 2	1	16.7	0		0		0		1	2.6
Hypersensitivity
Grade 2	0		0		1	16.7	0		1	2.6
Infections
Sinusitis/nasal polyps
Grade 2	0		0		0		1	4.8	1	2.6
Musculoskeletal*
Grade 2	0		0		1	16.7	3	14.3	4	10.3
Grade 3	1	16.7	0		0		1	4.8	2	5.1
Neurologic
Headache
Grade 2	0		0		0		1	4.8	1	2.6
Respiratory
Dyspnea
Grade 2	0		0		1	16.7	0		1	2.6
Pleural effusion
Grade2	1	16.7	0		0		0		1	2.6
Skin†
Grade 2	0		1	16.7	0		1	4.8	2	5.1
Urinary tract
Proteinuria
Grade 2	0		1	16.7	0		0		1	2.6

Abbreviation: MDX-1106, anti–programmed death-1 monoclonal antibody.

^*Musculoskeletal disorders include arthralgia, arthritis, myalgia, extremity pain, joint stiffness, back pain, bone pain, muscular weakness, and polymyalgia rheumatica.

^†Skin disorders include rash, erythema, pruritis, dry skin, alopecia, hyperhidrosis, lichenoid keratosis, and skin discoloration.